Wei Hou, Bryan Bridgeman, Greg Malnassy, Xianzhong Ding, Scott J. Cotler, Asha Dhanarajan, Wei Qiu – 2 March 2022 – Lenvatinib is a multikinase inhibitor approved as a first‐line therapy for advanced hepatocellular carcinoma (HCC). However, the development of drug resistance is common, and the underlying mechanisms governing this resistance are largely unknown. In this study, we established two lenvatinib‐resistant (LR) HCC cell lines and identified integrin subunit beta 8 (ITGB8) as a critical contributor to lenvatinib resistance in HCC.

Elizabeth J. Carey, John Eaton, Mitchell Clayton, Andrea Gossard, Sara Iqbal, Hamid Ullah, Nan Zhang, Richard Butterfield, Keith D. Lindor – 2 March 2022 – The purpose of this pilot study was to explore the efficacy, safety, and tolerability of vidofludimus calcium (VC) in the treatment of primary sclerosing cholangitis (PSC). This was a single‐arm open‐label pilot study with a cohort of 18 patients with PSC. Study patients received VC for a period of 6 months. The study was undertaken at two sites, Mayo Clinic, Rochester, MN, and Mayo Clinic, Phoenix, AZ.

Ezequiel Mauro, Juan Manuel Diaz, Lucrecia Garcia‐Olveira, Juan Carlos Spina, Lorena Savluk, Fernanda Zalazar, Julia Saidman, Martin De Santibañes, Juan Pekolj, Eduardo De Santibañes, Gonzalo Crespo, Juan G. Abraldes, Adrían Gadano – 2 March 2022 – Sarcopenia is a prevalent condition that predicts prognosis in patients awaiting liver transplantation (LT). The gold standard for the diagnosis of sarcopenia is the assessment of the muscular area at L3 with computed tomography (CT) scan (skeletal muscle index [SMI]), but the routine use of CT scan is limited in clinical practice.

2 March 2022

Michelle T. Jesse – 2 March 2022

Nan Lin, Yongping Lin, Jianfeng Xu, Dan Liu, Diange Li, Hongyu Meng, Maxime A. Gallant, Naoto Kubota, Dhruvajyoti Roy, Jason S. Li, Emmanuel C. Gorospe, Morris Sherman, Robert G. Gish, Ghassan K. Abou‐Alfa, Mindie H. Nguyen, David J. Taggart, Richard A. Van Etten, Yujin Hoshida, Wei Li – 2 March 2022 – The limited performance of guideline‐recommended abdominal ultrasound and serum alpha‐fetoprotein (AFP) highlights the urgent, unmet need for new biomarkers for more accurate detection of early hepatocellular carcinoma (HCC).

Maria Corina Plaz Torres, Ariel Jaffe, Rachel Perry, Elisa Marabotto, Mario Strazzabosco, Edoardo G. Giannini – 2 March 2022 – Type 2 diabetes mellitus is a recognized risk factor for HCC in patients with liver disease, independent from the etiology of their liver disease. Hence, prevention and treatment of type 2 diabetes mellitus and its underlying cause, insulin resistance, should be considered a treatment target for patients with liver disease.

Rosyli F. Reveron‐Thornton, Margaret L. P. Teng, Eunice Yewon Lee, Andrew Tran, Sean Vajanaphanich, Eunice X. Tan, Sanjna N. Nerurkar, Rui Xin Ng, Readon Teh, Debi Prasad Tripathy, Takanori Ito, Taku Tanaka, Nozomi Miyake, Biyao Zou, Connie Wong, Hidenori Toyoda, Carlos O. Esquivel, C. Andrew Bonham, Mindie H. Nguyen, Daniel Q. Huang – 1 March 2022 – Surgical resection for HCC remains a major curative treatment option, but it is unclear whether there are differences in outcomes by region and whether outcomes have improved over time.

Sapna Humar, Judy Jung, Sandra Krause, Nazia Selzner, Susan Abbey – 28 February 2022 – Anonymous living organ donation has recently become more common in select transplantation programs, with donors voluntarily offering a kidney or a lobe of their liver to those in need. These anonymous donations may be directed to a specific recipient or nondirected, and anonymity may be one way or reciprocal. Given their unique situation, we interviewed a cohort of anonymous living liver donors and explored their opinions surrounding anonymity and its implications in living liver donation.

Chenhua Wang, Ludi Zhang, Zhen Sun, Xiang Yuan, Baihua Wu, Jin Cen, Lei Cui, Kun Zhang, Chun Li, Jingqi Wu, Yajing Shu, Wenbin Sun, Jing Wang, Lijian Hui – 28 February 2022